Sage Therapeutics - SAGE Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $39.28
Forecasted Upside: 201.33%
Number of Analysts: 17
Breakdown:
1 Sell Ratings
13 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$13.04 As of 04/18/2024 01:00 AM ET

▲ +0.46 (3.66%)

1 month | 3 months | 12 months

Get New Sage Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for SAGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SAGE

^$39.28

▲ +201.33% Upside Potential

This price target is based on 17 analysts offering 12 month price targets for Sage Therapeutics in the last 3 months. The average price target is $39.28, with a high forecast of $294.00 and a low forecast of $14.00. The average price target represents a 201.33% upside from the last price of $13.04.

Current Consensus is Hold

The current consensus among 17 investment analysts is to hold stock in Sage Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
13 hold ratings
1 sell ratings

Ratings as of

10/26/2022

0 strong buy ratings
3 buy ratings
13 hold ratings
1 sell ratings

Ratings as of

1/24/2023

0 strong buy ratings
3 buy ratings
13 hold ratings
1 sell ratings

Ratings as of

4/24/2023

0 strong buy ratings
3 buy ratings
13 hold ratings
1 sell ratings

Ratings as of

7/23/2023

0 strong buy ratings
3 buy ratings
13 hold ratings
1 sell ratings

Ratings as of

10/21/2023

0 strong buy ratings
3 buy ratings
13 hold ratings
1 sell ratings

Ratings as of

1/19/2024

0 strong buy ratings
3 buy ratings
13 hold ratings
1 sell ratings

Ratings as of

3/19/2024

0 strong buy ratings
3 buy ratings
13 hold ratings
1 sell ratings

Ratings as of

4/18/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/18/2024	Scotiabank	Lower Target	Sector Outperform ➝ Sector Outperform	$34.00 ➝ $19.00	Low
4/18/2024	Oppenheimer	Lower Target	Market Perform ➝ Market Perform	$25.00 ➝ $17.00	Low
4/18/2024	Needham & Company LLC	Reiterated Rating	Hold		Low
4/18/2024	TD Cowen	Lower Target	Buy ➝ Buy	$30.00 ➝ $16.00	Low
4/17/2024	Wedbush	Reiterated Rating	Neutral ➝ Neutral	$24.00	N/A
4/17/2024	HC Wainwright	Reiterated Rating	Neutral ➝ Neutral	$28.00	N/A
4/17/2024	Bank of America	Downgrade	Neutral ➝ Underperform	$24.00 ➝ $14.00	Low
3/26/2024	JPMorgan Chase & Co.	Boost Target	Overweight ➝ Overweight	$24.00 ➝ $29.00	Low
2/28/2024	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $22.00	Low
2/15/2024	HC Wainwright	Boost Target	Neutral ➝ Neutral	$25.00 ➝ $28.00	Low
2/15/2024	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$21.00 ➝ $26.00	Low
12/18/2023	Stifel Nicolaus	Lower Target	Hold ➝ Hold	$22.00 ➝ $20.00	Low
12/12/2023	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold	$21.00	Low
11/8/2023	Royal Bank of Canada	Lower Target	Sector Perform ➝ Sector Perform	$22.00 ➝ $21.00	Low
11/8/2023	Wedbush	Boost Target	Neutral ➝ Neutral	$21.00 ➝ $22.00	Low
10/13/2023	The Goldman Sachs Group	Boost Target	Neutral ➝ Neutral	$22.00 ➝ $25.00	Low
9/8/2023	Bank of America	Lower Target	Neutral ➝ Neutral	$25.00 ➝ $24.00	Low
9/7/2023	Royal Bank of Canada	Lower Target	Sector Perform ➝ Sector Perform	$25.00 ➝ $22.00	Low
9/7/2023	Mizuho	Boost Target	Neutral ➝ Neutral	$19.00 ➝ $20.00	Low
9/1/2023	Scotiabank	Boost Target		$24.00 ➝ $27.00	Low
8/9/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$49.00 ➝ $20.00	Low
8/8/2023	TD Cowen	Lower Target	Outperform ➝ Outperform	$105.00 ➝ $28.00	Low
8/8/2023	Oppenheimer	Lower Target	Market Perform ➝ Market Perform	$24.00 ➝ $20.00	Low
8/8/2023	Truist Financial	Lower Target	Hold ➝ Hold	$40.00 ➝ $20.00	Low
8/8/2023	Mizuho	Lower Target	Neutral ➝ Neutral	$45.00 ➝ $19.00	Low
8/8/2023	HC Wainwright	Lower Target		$50.00 ➝ $27.00	Low
8/8/2023	The Goldman Sachs Group	Reiterated Rating	Buy ➝ Neutral	$75.00 ➝ $22.00	Low
8/8/2023	Needham & Company LLC	Downgrade	Buy ➝ Hold		Low
8/8/2023	Canaccord Genuity Group	Reiterated Rating	Buy ➝ Hold	$64.00 ➝ $21.00	Low
8/8/2023	Canaccord Genuity Group	Downgrade	Buy ➝ Hold	$64.00 ➝ $21.00	Low
8/7/2023	Barclays	Lower Target		$311.00 ➝ $294.00	Low
8/7/2023	Bank of America	Downgrade	Buy ➝ Neutral	$66.00 ➝ $25.00	N/A
8/7/2023	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$60.00 ➝ $22.00	N/A
8/7/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$70.00	N/A
8/7/2023	HC Wainwright	Reiterated Rating	Neutral ➝ Neutral	$50.00	N/A
8/7/2023	Wedbush	Downgrade	Outperform ➝ Neutral	$51.00 ➝ $22.00	N/A
8/7/2023	Oppenheimer	Downgrade	Outperform ➝ Market Perform		N/A
8/7/2023	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$71.00 ➝ $25.00	N/A
8/3/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$49.00	Low
7/27/2023	Scotiabank	Initiated Coverage	Outperform		Low
6/15/2023	Bank of America	Boost Target		$61.00 ➝ $66.00	Low
5/23/2023	Bank of America	Boost Target		$56.00 ➝ $61.00	Low
5/3/2023	VNET Group	Reiterated Rating	Maintains		Low
5/3/2023	Royal Bank of Canada	Boost Target		$60.00 ➝ $63.00	Low
3/13/2023	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$40.00 ➝ $60.00	Low
3/9/2023	HC Wainwright	Reiterated Rating	Neutral	$50.00	Low
2/17/2023	HC Wainwright	Reiterated Rating	Neutral	$50.00	Low
2/17/2023	Needham & Company LLC	Reiterated Rating	Buy	$70.00	N/A
2/17/2023	Citigroup	Boost Target	Neutral	$40.00 ➝ $46.00	Low
2/17/2023	Mizuho	Boost Target	Neutral	$37.00 ➝ $45.00	Low
1/3/2023	Guggenheim	Downgrade	Buy ➝ Neutral		Low
12/6/2022	JPMorgan Chase & Co.	Lower Target	Overweight	$92.00 ➝ $60.00	Low
11/21/2022	Morgan Stanley	Lower Target	Equal Weight	$53.00 ➝ $50.00	Low
11/11/2022	Guggenheim	Lower Target	Buy	$55.00 ➝ $48.00	Low
11/9/2022	BMO Capital Markets	Lower Target	Market Perform	$43.00 ➝ $40.00	Low
11/9/2022	HC Wainwright	Lower Target	Neutral	$55.00 ➝ $50.00	N/A
11/1/2022	Loop Capital	Initiated Coverage	Hold	$41.00	Low
8/3/2022	Citigroup	Lower Target		$41.00 ➝ $40.00	Low
8/2/2022	Stifel Nicolaus	Lower Target		$58.00 ➝ $56.00	Low
7/11/2022	SVB Leerink	Lower Target	Market Perform	$50.00 ➝ $40.00	N/A
6/3/2022	Citigroup	Boost Target		$41.00	Low
5/24/2022	The Goldman Sachs Group	Lower Target	Buy	$85.00 ➝ $73.00	High
5/4/2022	Mizuho	Lower Target		$41.00 ➝ $37.00	High
3/31/2022	Berenberg Bank	Initiated Coverage	Hold	$37.00	High
3/10/2022	Morgan Stanley	Lower Target	Equal Weight	$61.00 ➝ $57.00	Low
3/9/2022	Truist Financial	Lower Target	Hold	$60.00 ➝ $40.00	High
3/3/2022	Mizuho	Lower Target	Neutral	$44.00 ➝ $41.00	Medium
2/25/2022	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$95.00 ➝ $64.00	High
2/25/2022	SVB Leerink	Lower Target	Market Perform	$60.00 ➝ $50.00	High
2/17/2022	The Goldman Sachs Group	Lower Target	Buy	$96.00	High
1/6/2022	Needham & Company LLC	Boost Target	Buy	$79.00 ➝ $85.00	High
12/20/2021	SVB Leerink	Lower Target	Market Perform	$70.00 ➝ $60.00	Low
11/18/2021	Needham & Company LLC	Reiterated Rating	Buy	$78.00	Low
11/18/2021	Mizuho	Lower Target	Neutral	$52.00 ➝ $44.00	High
11/3/2021	Oppenheimer	Lower Target	Outperform	$84.00 ➝ $80.00	High
11/3/2021	HC Wainwright	Lower Target	Neutral	$80.00 ➝ $55.00	High
11/2/2021	Royal Bank of Canada	Lower Target	Sector Perform	$52.00 ➝ $48.00	High
11/2/2021	Guggenheim	Upgrade	Neutral ➝ Buy	$55.00	High
10/20/2021	Needham & Company LLC	Initiated Coverage	Buy	$84.00 ➝ $80.00	Low
10/20/2021	Oppenheimer	Lower Target	Positive ➝ Outperform	$100.00 ➝ $84.00	Low
10/18/2021	SVB Leerink	Reiterated Rating	Market Perform		High
10/12/2021	Morgan Stanley	Lower Target	Equal Weight	$81.00 ➝ $78.00	Low
10/7/2021	SVB Leerink	Reiterated Rating	Hold		Low
10/6/2021	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$100.00 ➝ $50.00	High
10/4/2021	Stifel Nicolaus	Lower Target	Buy	$95.00 ➝ $75.00	High
9/22/2021	Needham & Company LLC	Initiated Coverage	Buy	$84.00	High
8/4/2021	Royal Bank of Canada	Lower Target	Sector Perform	$60.00 ➝ $55.00	Medium
8/4/2021	HC Wainwright	Lower Target	Neutral	$86.00 ➝ $80.00	Medium
6/16/2021	SVB Leerink	Lower Target	Market Perform	$90.00 ➝ $70.00	High
6/16/2021	HC Wainwright	Reiterated Rating	Hold		High
6/16/2021	Stifel Nicolaus	Lower Target	Buy	$121.00 ➝ $95.00	High
6/16/2021	William Blair	Downgrade	Outperform ➝ Market Perform	$62.00	High
6/16/2021	BMO Capital Markets	Lower Target	Positive ➝ Market Perform	$87.00 ➝ $73.00	High
6/16/2021	Citigroup	Downgrade	Buy ➝ Neutral	$101.00 ➝ $68.00	High
5/5/2021	Mizuho	Lower Target	Neutral	$81.00 ➝ $77.00	Medium
4/19/2021	Morgan Stanley	Lower Target	Equal Weight	$87.00 ➝ $81.00	Low
4/12/2021	Mizuho	Reiterated Rating	Hold	$81.00	High
4/7/2021	Piper Sandler	Initiated Coverage	Overweight	$100.00	Medium
3/4/2021	Mizuho	Reiterated Rating	Buy ➝ Neutral	$81.00	High
3/2/2021	Morgan Stanley	Boost Target	Equal Weight	$83.00 ➝ $87.00	High
2/26/2021	Mizuho	Downgrade	Buy ➝ Neutral	$81.00	High
2/25/2021	Oppenheimer	Boost Target	Outperform	$90.00 ➝ $102.00	Low
2/25/2021	HC Wainwright	Boost Target	Neutral	$74.00 ➝ $86.00	High
2/25/2021	HC Wainwright	Reiterated Rating	Neutral	$74.00 ➝ $86.00	High
2/1/2021	Raymond James	Initiated Coverage	Market Perform		Low
1/22/2021	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$95.00	High
1/19/2021	Wedbush	Boost Target	Outperform	$83.00 ➝ $98.00	Low
1/4/2021	Guggenheim	Upgrade	Neutral ➝ Buy		N/A
1/4/2021	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$83.00 ➝ $86.00	N/A
12/4/2020	William Blair	Reiterated Rating	Buy		Low
12/4/2020	Mizuho	Upgrade	Neutral ➝ Buy	$77.00 ➝ $81.00	Low
12/1/2020	Truist Financial	Boost Target		$60.00 ➝ $70.00	Low
12/1/2020	Smith Barney Citigroup	Lower Target		$100.00 ➝ $93.00	Low
12/1/2020	Royal Bank of Canada	Lower Target		$86.00 ➝ $83.00	Low
12/1/2020	HC Wainwright	Lower Target	Neutral	$81.00 ➝ $74.00	Low
12/1/2020	Morgan Stanley	Lower Target	Equal Weight	$85.00 ➝ $83.00	Low
11/30/2020	Raymond James	Downgrade	Outperform ➝ Market Perform		Low
11/19/2020	Oppenheimer	Boost Target		$65.00 ➝ $94.00	Medium
11/16/2020	Bank of America	Boost Target	Buy	$72.00 ➝ $95.00	High
11/16/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$87.00 ➝ $85.00	High
11/10/2020	Truist Financial	Boost Target	Hold	$35.00 ➝ $60.00	Low
11/6/2020	Smith Barney Citigroup	Boost Target		$67.00 ➝ $100.00	Low
11/6/2020	Mizuho	Boost Target	Neutral	$53.00 ➝ $77.00	Medium
11/6/2020	BMO Capital Markets	Boost Target	Outperform	$79.00 ➝ $89.00	Medium
11/6/2020	HC Wainwright	Boost Target	Neutral	$76.00 ➝ $81.00	Medium
10/20/2020	Royal Bank of Canada	Boost Target	Outperform	$75.00 ➝ $84.00	Low
10/16/2020	BMO Capital Markets	Boost Target	Positive ➝ Outperform	$65.00 ➝ $79.00	High
9/11/2020	Citigroup	Boost Target	Positive ➝ Buy	$54.00 ➝ $67.00	Low
9/11/2020	Wedbush	Upgrade	Neutral ➝ Outperform	$40.00 ➝ $65.00	Low
8/24/2020	Morgan Stanley	Boost Target	Overweight	$85.00 ➝ $87.00	Medium
8/11/2020	Royal Bank of Canada	Reiterated Rating	Buy		Medium
8/11/2020	Oppenheimer	Boost Target	Outperform	$50.00 ➝ $65.00	High
8/10/2020	Raymond James	Upgrade	Market Perform ➝ Outperform	$70.00	Low
8/10/2020	Mizuho	Reiterated Rating	Hold	$44.00	High
5/26/2020	Royal Bank of Canada	Boost Target	Outperform	$72.00 ➝ $75.00	Low
5/8/2020	SunTrust Banks	Lower Target	Hold	$37.00 ➝ $35.00	High
5/8/2020	Royal Bank of Canada	Boost Target	Outperform	$71.00 ➝ $72.00	High
5/8/2020	Wedbush	Downgrade	Outperform ➝ Neutral	$36.00 ➝ $37.00	Medium
5/8/2020	Mizuho	Boost Target	Neutral	$36.00 ➝ $44.00	Medium
4/28/2020	Royal Bank of Canada	Boost Target	Outperform	$68.00 ➝ $71.00	High
4/19/2020	Guggenheim	Downgrade	Buy ➝ Neutral		High
4/9/2020	BMO Capital Markets	Lower Target	Outperform	$86.00 ➝ $65.00	Medium
4/9/2020	SunTrust Banks	Lower Target	Hold	$40.00 ➝ $37.00	Medium
4/8/2020	Royal Bank of Canada	Boost Target	Outperform	$60.00 ➝ $68.00	High
4/8/2020	Wedbush	Lower Target	Outperform	$56.00 ➝ $36.00	High
4/8/2020	Oppenheimer	Lower Target	Outperform	$60.00 ➝ $50.00	High
4/8/2020	Citigroup	Boost Target	Buy	$48.00 ➝ $54.00	High
4/8/2020	Guggenheim	Downgrade	Buy ➝ Neutral		High
4/8/2020	Mizuho	Lower Target	Neutral	$58.00 ➝ $36.00	High
3/26/2020	SunTrust Banks	Lower Target	Hold	$50.00 ➝ $40.00	Medium
3/22/2020	HC Wainwright	Reiterated Rating	Hold	$78.00	Low
3/20/2020	LADENBURG THALM/SH SH	Reiterated Rating	Hold	$28.00	High
3/19/2020	Oppenheimer	Lower Target		$97.00 ➝ $60.00	Low
3/19/2020	SVB Leerink	Boost Target	Market Perform	$45.00 ➝ $63.00	Low
3/19/2020	Guggenheim	Lower Target	Buy	$85.00 ➝ $65.00	Low
3/19/2020	Citigroup	Lower Target	Buy	$71.00 ➝ $48.00	Low
3/18/2020	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$73.00 ➝ $60.00	High
3/11/2020	Mizuho	Reiterated Rating	Hold	$58.00	High
3/5/2020	Citigroup	Initiated Coverage	Buy	$71.00	High
3/3/2020	Morgan Stanley	Lower Target	Overweight	$125.00 ➝ $117.00	Medium
2/28/2020	SunTrust Banks	Lower Target	Hold	$60.00 ➝ $50.00	High
2/28/2020	LADENBURG THALM/SH SH	Reiterated Rating	Hold	$52.00	High
2/28/2020	HC Wainwright	Lower Target	Neutral	$87.00 ➝ $78.00	High
2/28/2020	Mizuho	Lower Target	Neutral	$69.00 ➝ $58.00	High
2/27/2020	Cowen	Reiterated Rating	Buy	$96.00	High
2/27/2020	Mizuho	Reiterated Rating	Hold	$69.00	High
2/5/2020	Mizuho	Initiated Coverage	Neutral	$69.00	Low
1/7/2020	Bank of America	Boost Target		$85.00 ➝ $98.00	Medium
12/6/2019	Oppenheimer	Lower Target		$190.00 ➝ $100.00	Medium
12/6/2019	JPMorgan Chase & Co.	Lower Target	Overweight	$200.00 ➝ $105.00	Low
12/6/2019	LADENBURG THALM/SH SH	Downgrade	Buy ➝ Neutral		Low
12/6/2019	Royal Bank of Canada	Lower Target	Outperform	$190.00 ➝ $100.00	High
12/6/2019	Morgan Stanley	Lower Target	Overweight	$217.00 ➝ $125.00	High
12/6/2019	BMO Capital Markets	Reiterated Rating	Outperform	$92.00	High
12/6/2019	SVB Leerink	Upgrade	Underperform ➝ Market Perform		High
12/6/2019	HC Wainwright	Lower Target	Neutral	$160.00 ➝ $87.00	High
12/5/2019	The Goldman Sachs Group	Lower Target		$227.00 ➝ $263.00	High
12/5/2019	Piper Sandler Companies	Lower Target	Overweight	$206.00 ➝ $125.00	High
12/5/2019	Guggenheim	Lower Target	Buy	$200.00 ➝ $110.00	High
12/5/2019	Cowen	Reiterated Rating	Buy	$96.00	High
12/5/2019	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$73.00	High
12/5/2019	Wedbush	Lower Target	Outperform	$203.00 ➝ $90.00	High
12/5/2019	SunTrust Banks	Downgrade	Buy ➝ Hold	$210.00 ➝ $70.00	High
11/25/2019	Royal Bank of Canada	Reiterated Rating	Buy	$235.00	Low
11/24/2019	Morgan Stanley	Reiterated Rating	Buy	$217.00	Medium
11/20/2019	Stifel Nicolaus	Reiterated Rating	Buy		Low
10/30/2019	HC Wainwright	Initiated Coverage	Neutral	$160.00	Low
8/7/2019	Oppenheimer	Lower Target	Outperform	$200.00 ➝ $190.00	Medium
7/25/2019	Oppenheimer	Boost Target		$170.00 ➝ $200.00	Medium
7/24/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
7/24/2019	William Blair	Reiterated Rating	Buy		Low
5/22/2019	Wedbush	Initiated Coverage	Outperform ➝ Outperform	$207.00	Low
5/5/2019	Oppenheimer	Set Target	Buy	$170.00	Medium
5/2/2019	LADENBURG THALM/SH SH	Set Target	Buy	$220.00	Low
4/26/2019	Raymond James	Reiterated Rating	Market Perform		Medium
4/25/2019	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$195.00	Low

(Data available from 4/19/2019 forward)

News Sentiment Rating

-0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

3 very positive mentions
10 positive mentions
6 negative mentions
5 very negative mentions

Mentions as of

9/22/2023

3 very positive mentions
5 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

10/22/2023

4 very positive mentions
10 positive mentions
2 negative mentions
3 very negative mentions

Mentions as of

11/21/2023

1 very positive mentions
5 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

12/21/2023

2 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/20/2024

16 very positive mentions
15 positive mentions
4 negative mentions
1 very negative mentions

Mentions as of

2/19/2024

12 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/20/2024

5 very positive mentions
16 positive mentions
11 negative mentions
3 very negative mentions

Mentions as of

4/19/2024

Current Sentiment

Recent Stories by Sentiment

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $13.04

$12.20

$13.50

50 Day Range

MA: $20.06

$12.57

$25.75

52 Week Range

Now: $13.04

$10.92

$59.99

Volume

1,757,638 shs

Average Volume

955,460 shs

Market Capitalization

$783.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Sage Therapeutics?: The following sell-side analysts have issued reports on Sage Therapeutics in the last year: Bank of America Co., Barclays PLC, Canaccord Genuity Group Inc., Deutsche Bank Aktiengesellschaft, HC Wainwright, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Royal Bank of Canada, Scotiabank, Stifel Nicolaus, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., VNET Group, Inc., and Wedbush.
View the latest analyst ratings for SAGE.
What is the current price target for Sage Therapeutics?: 18 Wall Street analysts have set twelve-month price targets for Sage Therapeutics in the last year. Their average twelve-month price target is $39.28, suggesting a possible upside of 201.3%. Barclays PLC has the highest price target set, predicting SAGE will reach $294.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $14.00 for Sage Therapeutics in the next year.
View the latest price targets for SAGE.
What is the current consensus analyst rating for Sage Therapeutics?: Sage Therapeutics currently has 1 sell rating, 13 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SAGE, but not buy more shares or sell existing shares.
View the latest ratings for SAGE.
What other companies compete with Sage Therapeutics?: Other companies that are similar to Sage Therapeutics include ABIVAX Société Anonyme, Innoviva, Zentalis Pharmaceuticals, Cassava Sciences and Arcutis Biotherapeutics. Learn More about companies similar to Sage Therapeutics.
How do I contact Sage Therapeutics' investor relations team?: Sage Therapeutics' physical mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is (617) 299-8380 and its investor relations email address is [email protected]. The official website for Sage Therapeutics is www.sagerx.com. Learn More about contacing Sage Therapeutics investor relations.

Sage Therapeutics - SAGE Stock Price Target and Predictions

Analyst Price Target for SAGE

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

-0.04 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Sage Therapeutics?

What is the current price target for Sage Therapeutics?

What is the current consensus analyst rating for Sage Therapeutics?

What other companies compete with Sage Therapeutics?

How do I contact Sage Therapeutics' investor relations team?